65,437 trials
Seasonal Allergic Rhinitis · SAR
Primary: Change From Baseline in the Average Morning (AM) and Evening (PM) Subject-Reported Reflective Total Nasal Symptom Score (rTNSS) During the Two Weeks of Treatment — -1.9…
Carcinoma, Non-Small-Cell Lung · Colorectal Cancer · Malignant Melanoma
Primary: Number of Participants With Severe Adverse Events (AEs), Serious Adverse Events (SAEs), Drug-Related AEs, Deaths, Discontinuation of Study Drug Due to AE, Dose-Limiting…
Peanut Allergy
Primary: Number of Participants That Tolerated Rapid Oral Peanut Desensitization to a Dose of 500 mg Peanut Flour (Cumulative Dose, 1,000 mg) — 13 participants
Type 2 Diabetes
Primary: Change From Baseline in Homeostatic Model Assessment Fasting Beta Cell Function (HOMA % B) at 4 Years — 50.2; 48.3 Percentage of Beta Cell Function — p=0.24
Meningococcal Disease · Meningococcal Meningitis
Primary: Human Serum Bactericidal Activity (hSBA) Geometric Mean Titers (GMTs) Against 3 Neisseria.Meningitidis (N. Meningitidis) Serogroup B Reference Strains. — 111; 111; 9.27…
Plaque Psoriasis
Primary: Number of Patients With Adverse Events — 4; 5; 7; 6 participants
Dupuytren's Contracture
Primary: Percent Change From Baseline in Total Fixed Flexion — 74.41 percentage of contracture change
Osteoarthritis
Primary: Change in Knee Extensor Torque — 130.1 Nm
Venous Thromboembolism
Primary: Incidence of Subjects With Venous Thromboembolism Events. — 7.4; 13.9 percent of participants with VTE events — p=<0.001
Obstructive Sleep Apnea
Primary: Apnea-hypopnea Index (AHI) at One Year — 35.3; 39.6 events per hour
Rheumatoid Arthritis
Primary: Arthritis Impact Measurement Scale - Version 2 (AIMS2) Main Component Score at Baseline — 3.5; 4.8; 7.3 units on a scale
Anesthesia, General
Primary: Time to Extubation — 13.0; 12.5 minutes
High Risk Neuroblastoma
Primary: Percentage of Patients Who Experienced a Significant (CTC Grade 3-5) Nonhematologic Toxicity of Interest (Pain, Hypotension, Allergic Reactions, Capillary Leak Syndrome…
Edema
Primary: Number of Participants Who Showed Improvement in Under Eye Swelling and Dark Circles Relative to Baseline Per Intervention — 0; 0 participants — p==1
Major Depressive Disorder
Primary: Change in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Total Score From Augmentation Baseline (Week 8) to Week 16 (Double-blind Phase, Dose Response Evaluable Set)…